CARDIOVASCULAR JOURNAL OF AFRICA • Vol 23, No 4, May 2012
AFRICA
231
62. Stenvinkel P. Endothelial dysfunction and inflammation – is there a
link?
Nephrol Dial Transplant
2001;
16
: 1968–1971.
63. Zhang C, Xu X, Potter BJ, Wang W,
et al.
TNF-
α
contributes to
endothelial dysfunction in ischemia/reperfusion injury.
Arterioscler
Thromb Vasc Biol
2006;
26
: 475–480.
64. Balakumar P, Kaur T, Singh M. Potential target sites to modulate vascu-
lar endothelial dysfunction: current perspectives and future directions.
Toxicology
2008;
245
(1–2): 49–64.
65. Münzel T, Sinning C, Post F,
et al
. Pathophysiology, diagnosis and
prognostic implication of endothelial dysfunction
. Ann Med
2008;
40
:
180–196.
66. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated
dilation and cardiovascular event prediction: does nitric oxide matter?
Hypertension
2011;
57
(3): 363–369.
67. Kim F, Gallis B, Corson MA. TNF-alpha inhibits flow and insulin sign-
aling leading to NO production in aortic endothelial cells.
Am J Physiol
Cell Physiol
2001;
280
(5): C1057–1065.
68. Bove K, Neumann P, Gertzberg N, Johnson A. Role of ecNOS-derived
NO in mediating TNF-induced endothelial barrier dysfunction.
Am J
Physiol Lung Cell Mol Physiol
2001;
280
(5): L914–922
69. Xia Z, Luo T, Liu HM, Wang F, Xia ZY, Irwin MG, Vanhoutte PM.
L-arginine enhances nitrative stress and exacerbates tumor necrosis
factor-alpha toxicity to human endothelial cells in culture: prevention
by propofol.
J Cardiovasc Pharmacol
2010;
55
(4): 358–367.
70. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC.
Tumor necrosis factor-alpha reduces argininosuccinate synthase expres-
sion and nitric oxide production in aortic endothelial cells.
Am J Physiol
Heart Circ Physiol
2007;
293
(2): H1115–1121.
71. Kiettisanpipop P, Lertsapcharom P, Chotivittayatakorn P,
et al
. Plasma
levels of nitric oxide in children with congenital heart disease and
increased pulmonary blood flow.
J Med Assoc Thai
2007;
90
: 2053–
2057.
72. Best PJM, Berger PB, Miller VM,
et al
. The effect of estrogen replace-
ment therapy on plasma nitric oxide and endothelin-1 levels in post-
menopausal women.
Ann Intern Med
1998;
128
: 285–288.
73. Heiss C, Lauer T, Dejam A,
et al.
Plasma nitroso compounds are
decreased in patients with endothelial dysfunction.
J Am Coll Cardiol
2006;
47
: 573–579.
74. Landim MBP, Filho AC, Chagas ACP. Asymmetric dimethylarginine
(ADMA) and endothelial dysfunction: implications for atherogenesis.
Clinics
2009;
64
: 471–478.
75. Sydow K, Münzel T. ADMA and oxidative stress.
Atherosclerosis Suppl
2003;
4
: 41–51.
76. Krempl TK, Maas R, Sydow K, Meinertz T, Böger RH, Kähler J.
Elevation of asymmetric dimethylarginine in patients with unstable
angina and recurrent cardiovascular events.
Eur Heart J
2005;
26
(18):
1846–1851.
77. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin
EJ,
et al
. Plasma asymmetric dimethylarginine and incidence of
cardiovascular disease and death in the community.
Circulation
2009;
119
(12): 1592–1600.
78. Boos CJ, Lip GYH, Blann AD. Circulating endothelial cells in cardio-
vascular disease.
J Am Coll Cardiol
2006;
48
: 1538–1547.
79. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a
novel marker of endothelial damage.
Clin Chim Acta
2006;
373
: 17–26.
80. Souza JM, Peluffo G, Radi R. Protein tyrosine nitration-functional
alteration or just a biomarker?
Free Radic Biol Med
2008;
45
: 357–366.
81. Hurst JK. Whence nitrotyrosine?
J Clin Invest
2002;
109
: 1287–1289.
82. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in
health and disease.
Physiol Rev
2007;
87
: 315–424.
83. Jin J, Wang C, Tao Y,
et al
. Determination of 3-nitrotyrosine in human
urine samples by surface plasmon resonance immunoassay.
Sensors
Actuators B
2011;
153
: 164–169.
84. Molavi B, Mehta JL. Oxidative stress in cardiovascular disease:
molecular basis of its deleterious effects, its detection and therapeutic
consideration
. Curr Opin Cardiol
2004;
19
: 488–493.
85. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft
J,
et al
. Methods for evaluating endothelial function: a position state-
ment from the European Society of Cardiology Working Group on
Peripheral Circulation.
Eur J Cardiovasc Prev Rehabil
2011 Mar 11.
[Epub ahead of print].
86. Huang NF, Kurpinski K, Fang Q, Lee RJ, Li S. Proteomic identification
of biomarkers of vascular injury.
Am J Transl Res
2011;
3
(2): 139–148.
87. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson
J,
et al
. Oral L-arginine improves endothelium-dependent dilation
in hypercholesterolemic young adults.
J Clin Invest
1996;
97
(8):
1989–1994.
88. Javanmard SH, Nematbakhsh M, Sanei MH. Early prevention by
L-arginine attenuates coronary atherosclerosis in a model of hyper-
cholesterolemic animals; no positive results for treatment.
Nutr Metab
(Lond)
2009;
6
: 13.
89. Yang Z, Ming X-Z. Recent advances in understanding endothelial
dysfunction in atherosclerosis.
Clin Med Res
2006;
4
: 53–65.
90. Ruberg FL, Loscalzo J. Inflammation and atherothrombosis. In:
Loscalzo J (ed).
Molecular Mechanisms of Atherosclerosis
. London:
Taylor and Francis 2005: 45–60.
91. Libby P. Changing concepts of atherogenesis.
J Intern Med
2000;
247
:
349–358.
92. Widlansky ME, Gokce N, Keaney JF,
et al
. The clinical implications
of endothelial dysfunction.
J Am Coll Cardiol
2003;
42
: 1149–1160.
93. John S, Schlaich M, Langefelm M,
et al.
Increased bioavailabil-
ity of nitric oxide after lipid lowering therapy in hypercholester-
olemic patients: a randomized, placebo-controlled, double blind study.
Circulation
1998;
98
: 211–216.
HEALTHCARE
